STOCK TITAN

Innate Pharma Sa - IPHA STOCK NEWS

Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.

Company Overview

Innate Pharma SA (IPHA) is a clinical-stage biotechnology company that has made significant strides in the field of immuno-oncology by developing innovative therapeutic antibodies. By harnessing the innate immune system, the company addresses unmet medical needs in cancer treatment. Its work in mobilizing natural killer (NK) cells to recognize and eradicate cancer cells places it at a unique intersection of cutting‐edge science and clinical application.

Clinical Pipeline and Technological Innovations

The company has built a diversified pipeline comprising first-in-class clinical stage antibodies and preclinical candidates. Its proprietary platforms, such as the antibody-based NK cell engager therapeutics framework, exemplify its commitment to advancing immunotherapies. This technological edge has allowed Innate Pharma SA to explore a broad range of cancer indications and develop treatments that aim to provide improved outcomes and more targeted therapeutic effects.

Strategic Collaborations and Revenue Model

Revenue for Innate Pharma SA is generated primarily through research agreements, licensing deals, and strategic collaborations with established biopharma companies. These partnerships not only provide financial support but also validate the scientific merit of its approach. Collaborations with industry giants have enabled the company to accelerate clinical development and expand its research capabilities, underlining its credibility within the scientific community.

Innovative Approach and Core Expertise

At the core of Innate Pharma SA’s strategy is an innovative approach that leverages the innate immune system’s natural ability to combat cancer. The company’s deep expertise in natural killer cell biology distinguishes its methods from conventional immunotherapies that primarily target adaptive immune responses. This focused approach has paved the way for the discovery and development of novel checkpoint inhibitors and other therapeutic antibodies which are designed to reinvigorate the immune response against malignancies.

Market Position and Industry Significance

Innate Pharma SA is positioned as a pioneering entity within the immunotherapy sector. Its innovative research and comprehensive pipeline contribute to its reputation as an organization with substantial scientific industrial relevance. By addressing complex cancer biology through innovative solutions, the company plays a critical role in the broader narrative of modern oncology and immunotherapy. The content herein offers an in-depth perspective on how its clinical-stage initiatives and collaborative model set it apart in a competitive landscape.

Research, Development, and Operational Excellence

The company emphasizes a rigorous research and development ethos, meticulously navigating the challenges and complexities of immuno-oncology. Its operational strategy is built on scientific excellence and the clear intent to explore transformative cancer therapies. This approach not only reinforces its research credentials but also ensures that every innovation is subjected to strict scientific scrutiny, thereby upholding high standards of quality and efficacy.

Summary

In summary, Innate Pharma SA is a clinical-stage biotechnology company committed to transforming cancer treatment through its advanced immunotherapies. With a diversified pipeline, robust technological innovations, and strategic partnerships, the company represents a notable presence in the landscape of immuno-oncology. Its work in harnessing the innate immune system through novel therapeutic antibodies continues to influence the evolution of cancer treatment modalities in a meaningful way.

Rhea-AI Summary
Innate Pharma announced the advancement of Sanofi-developed NK cell engager SAR443579 / IPH6101 to Phase 2 for blood cancer patients. The first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial, triggering a €4m milestone payment to Innate. SAR443579 is being evaluated as a monotherapy for blood cancers with high unmet needs, including R/R AML, B-cell acute lymphoblastic leukemia, and high-risk myelodysplasia. The drug received FDA Fast Track Designation for the treatment of acute myeloid leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
-
Rhea-AI Summary
Innate Pharma SA announces promising preclinical data for IPH45, a novel exatecan-Antibody Drug Conjugate targeting Nectin-4, showing stronger activity than EV in urothelial tumors. IPH45 demonstrates anti-tumor efficacy in various solid tumors and EV-refractory models, with plans for IND in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
-
Rhea-AI Summary
Innate Pharma SA (Nasdaq: IPHA) executives to attend Van Lanschot Kempen conference in Amsterdam on April 16-17, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Innate Pharma (IPHA) files 2023 Universal Registration Document and annual report on Form 20-F with AMF and SEC, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
-
Rhea-AI Summary
Innate Pharma reports positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome, licensing of a fourth NK cell engager ANKET® by Sanofi, and other significant milestones achieved in 2023. The company's cash position stands at €102.3 million as of December 31, 2023, with a cash runway to the end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
-
Rhea-AI Summary
Innate Pharma SA executives to participate in the 2nd Annual H.C. Wainwright Cell Therapy Virtual Conference on March 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) announced a conference call on March 21, 2024, to discuss financial results for the full year ending December 31, 2023. Key participants include the CEO, CMO, COO, CFO, and President of US Operations. The event will be live webcasted and accessible via telephone. A replay will be available on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
-
Rhea-AI Summary
Innate Pharma announces that its preclinical asset IPH45, a topoisomerase I inhibitor ADC targeting Nectin-4, has been selected for oral presentation at the AACR Annual Meeting 2024. The abstract highlights promising preclinical data showing effective tumor growth inhibition and a favorable safety profile, advancing IPH45 towards clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
conferences clinical trial
-
Rhea-AI Summary
Innate Pharma SA initiates Phase 1/2 trial for IPH6501, a CD20-targeting tetraspecific NK cell engager for B-cell Non-Hodgkin's Lymphomas. The study aims to enroll up to 184 patients, with the first patient already dosed. IPH6501 co-engages CD20 on malignant B cells and three NK cell receptors, enhancing cytotoxic activity. The IL-2 variant in IPH6501 provides proliferation signals to NK cells, offering a promising alternative to T cell therapies. Dr. Sonia Quaratino and Dr. Lorenzo Falchi express optimism about IPH6501's potential in treating refractory B-cell NHL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
Rhea-AI Summary
Innate Pharma (IPH; IPHA) to participate in Leerink Partners Global Biopharma Conference 2024 in Miami, Florida from March 11-13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences

FAQ

What is the current stock price of Innate Pharma Sa (IPHA)?

The current stock price of Innate Pharma Sa (IPHA) is $1.91 as of April 1, 2025.

What is the market cap of Innate Pharma Sa (IPHA)?

The market cap of Innate Pharma Sa (IPHA) is approximately 160.1M.

What is Innate Pharma SA's core business?

Innate Pharma SA is focused on developing innovative immunotherapies that harness the innate immune system to improve cancer treatment outcomes using therapeutic antibodies.

How does the company generate revenue?

Revenue is primarily generated through research collaboration agreements, licensing deals, and strategic partnerships with established biopharmaceutical companies.

What distinguishes Innate Pharma SA’s approach to cancer treatment?

The company leverages its deep expertise in natural killer cell biology and innovative antibody platforms to develop therapies that mobilize the innate immune system against cancer cells.

How diversified is the company’s clinical pipeline?

Innate Pharma SA has built a diversified pipeline including first-in-class clinical stage antibodies and preclinical candidates designed to target a broad range of cancer indications.

What role do strategic collaborations play in the company’s operations?

Strategic collaborations with major biopharmaceutical companies provide validation for its scientific innovations while supporting accelerated clinical development and expanding research capabilities.

How does Innate Pharma SA differentiate itself from competitors?

Its unique focus on leveraging the innate immune system, combined with proprietary therapeutic platforms and a strong pipeline of innovative antibodies, sets it apart in the competitive immuno-oncology space.
Innate Pharma Sa

Nasdaq:IPHA

IPHA Rankings

IPHA Stock Data

160.08M
83.83M
0.3%
0.55%
Biotechnology
Healthcare
Link
France
Marseille